Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ELEDON PHARMACEUTICALS INC
ELDN | US
3.46
USD-0.13
-3.48%
ELDN | US
Loading StockChartView...
About ELEDON PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
3.46
Open
3.61
High
3.61
Low
3.40
Eledon Pharmaceuticals Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart an anti-CD40L antibody with high affinity for CD40 Ligand a biological target with therapeutic potential. It has a collaboration agreement with eGenesis Inc. The company was formerly known as Novus Therapeutics Inc. and changed its name to Eledon Pharmaceuticals Inc. in January 2021. Eledon Pharmaceuticals Inc. is headquartered in Irvine California.
View LessELDN | US
Risk
86.0
Sharpe
-0.02
Luna's Score
37/100
Recommendation
Sell
Luna says (ELDN | US)
What's Working
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
96.9%1 month
86.0%3 months
75.1%6 months
105.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
6.60
Fwd. PE
5.39
Price to book
1.31
Debt to equity
-0.08
Debt to assets
0.01
Ent. to EBITDA
0.84
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-36.86M
MarketCap
143.39M
MarketCap(USD)
143.39M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-70.71
Short ratio
1.57
Short perc.
0.36
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.13
Range1M
1.52
Range3M
2.25
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.02
Price X volume
5.80M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.84 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | 6.60 | 41.03 | Cheaper |
| Price to Book | 1.31 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 75.06 | 72.80 | Par |
| Debt to Equity | -0.08 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 143.39M | 3.66B | Emerging |
